Vicore Pharma Holding AB (publ) (STO:VICO)

Market Cap	2.84B
Revenue (ttm)	6.00M
Net Income (ttm)	-311.88M
Shares Out	234.61M
EPS (ttm)	-1.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	420,864
Average Volume	733,358
Open	12.10
Previous Close	12.10
Day's Range	11.66 - 12.10
52-Week Range	6.09 - 17.24
Beta	0.34
RSI	74.88
Earnings Date	Aug 22, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 29
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VICO